Search

Home > Diabetes Knowledge into Practice Podcast > GLP-1 RA formulations & adherence | With Prof. Stephen Bain


	Podcast:		Diabetes Knowledge into Practice Podcast
	Episode:		GLP-1 RA formulations & adherence \| With Prof. Stephen Bain
	Category:		Health
	Duration:		00:11:17
	Publish Date:		2021-10-26 04:00:00
	Description:		While we have lots of safety and efficacy data for GLP-1 RAs, including head-to-head trials comparing therapies, real-world medication adherence and persistence is typically much lower. So how can we help patients to maximise the chances of treatment success? Join Prof. Stephen Bain for a discussion of how to implement strategies to support patients in starting GLP-1 RA therapy. We’ve got a new website! Find it at diabetes.knowledgeintopractice.com, where you can see all past episodes of the podcast as well as other free CME resources. Follow us on Twitter (@dkipractice) or connect on LinkedIn. References: Guerci B, et al. Lack of Treatment Persistence and Treatment Nonadherence as Barriers to Glycaemic Control in Patients with Type 2 Diabetes. Diabetes Ther. 2019 Apr;10(2):437-449. van Onzenoort HA, Menger FE, Neef C, Verberk WJ, Kroon AA, de Leeuw PW, van der Kuy PH. Participation in a clinical trial enhances adherence and persistence to treatment: a retrospective cohort study. Hypertension. 2011 Oct;58(4):573-8. Weeda ER, Muraoka AK, Brock MD, Cannon JM. Medication adherence to injectable glucagon-like peptide-1 (GLP-1) receptor agonists dosed once weekly vs once daily in patients with type 2 diabetes: A meta-analysis. Int J Clin Pract. 2021 Sep;75(9):e14060. Disclosures: Professor Stephen Bain declares no relevant financial relationships within the past 12 months. Target Audience This educational activity is intended for an international audience of non-US and non-UK HCPs. Funding This independent educational activity is supported by an educational grant from Novo Nordisk A/S. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; Novo Nordisk A/S has had no influence on the content of this education.
	Total Play:		0